Difference between revisions of "Autoimmune cytopenia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
m |
||
Line 4: | Line 4: | ||
|- | |- | ||
| style="background-color:#F0F0F0; width:15%" |[[File:Mistryrh.jpeg|frameless|upright=0.3|center]] | | style="background-color:#F0F0F0; width:15%" |[[File:Mistryrh.jpeg|frameless|upright=0.3|center]] | ||
− | | style="width:35%" |<big>Ronak H. Mistry, DO<br>Vanderbilt University<br>Nashville, TN</big><br>[https://www.linkedin.com/in/ronak-mistry-0482864b/ LinkedIn] | + | | style="width:35%" |<big>Ronak H. Mistry, DO<br>Vanderbilt University<br>Nashville, TN</big><br>[https://www.linkedin.com/in/ronak-mistry-0482864b/ LinkedIn]<br>[[File:Social-twitter-icon.png|frameless|upright=0.1]] [https://twitter.com/rmistry91 @rmistry91] |
|style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]] | |style="background-color:#F0F0F0; width:15%"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.3|center]] | ||
|style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Vanderbilt University<br>Nashville, TN</big> | |style="width:35%"|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Vanderbilt University<br>Nashville, TN</big> |
Revision as of 14:57, 15 October 2021
Page editor | Section editor | ||
---|---|---|---|
Ronak H. Mistry, DO Vanderbilt University Nashville, TN @rmistry91 |
Benjamin Tillman, MD Vanderbilt University Nashville, TN |
2 regimens on this page
2 variants on this page
|
This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.
Relapsed or refractory
Alemtuzumab monotherapy
back to top |
Regimen
Study | Evidence | Efficacy |
---|---|---|
Willis et al. 2001 | Phase II | ORR: 71% |
Immunosuppressive therapy
- Alemtuzumab (Campath) as follows:
- Test dose: 1 mg IV over 60 minutes once
- Days 1 to 10: 10 mg IV over 4 hours once per day
10-day course
References
- Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. link to original article contains verified protocol PubMed
Sirolimus monotherapy
back to top |
Regimen
Study | Evidence | Efficacy |
---|---|---|
Bride et al. 2015 | Phase II | Durable CR observed in patients with ALPS |
Immunosuppressive therapy
- Sirolimus (Rapamune) 2 to 2.5 mg/m2/day PO
- See manuscript for recommended dose adjustments
6-month course, extended for those with a favorable response
References
- Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. link to original article link to PMC article contains protocol PubMed